High turnover of tissue factor enables efficient intracellular delivery of Antibody-drug conjugates

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1130-1140

  De Goeij, Bart E C G ^a   Satijn, David ^a   Freitag, Claudia M ^a   Wubbolts, Richard ^b   Bleeker, Wim K ^a   Khasanov, Alisher ^c   Zhu, Tong ^c   Chen, Gary ^c   Miao, David ^c   Van Berke, Patrick H C ^a   Parren, Paul W H I ^a,d,e  

^a GENMAB   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Concortis Biosystems Corp ^*  (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DUOSTATIN 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROCOAGULANT; THROMBOPLASTIN; TOXIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIBODY; BLOOD CLOTTING FACTOR 7A; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; IMMUNOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; APOPTOSIS; COMPARATIVE STUDY; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NEOPLASMS, EXPERIMENTAL;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FACTOR VIIA; HUMANS; IMMUNOTOXINS; LYSOSOMES; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942089019     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0798     Document Type: Article

References (45)

1. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
2. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47.
3. Burris HA. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011;11:807-19.
4. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014;74:1214-26.
5. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20:123-8.
6. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-8.
7. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood 2002;99:4562-7.
8. Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L. Tissue factor expression correlates with disease-specific survival in patients with nodenegative muscle-invasive bladder cancer. Int J Cancer 2008;122:1592-7.
9. Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007;96:290-5.
10. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, et al. hIcon1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer 2010;103:812-9.
11. Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, et al. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hIcon1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer 2011;11.
12. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-5.
13. Wojtukiewicz MZ, Zacharski LR, Rucinska M, Zimnoch L, Jaromin J, Rozanska-Kudelska M, et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost 1999;82:1659-62.
14. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor in glioma. Noshuyo Byori 1996;13:115-8.
15. Jiang X, Zhu S, Panetti TS, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb Haemost 2008;100:127-33.
16. Hansen CB, Pyke C, Petersen LC, Rao LV. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood 2001;97:1712-20.
17. Mandal SK, Pendurthi UR, Rao LV. Cellular localization and trafficking of tissue factor. Blood 2006;107:4746-53.
18. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997;100:2276-85.
19. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009;27:4834-8.
20. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Eng J Med 2012;367:1783-91.
21. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51.
22. de Goeij BE, Peipp M, De Haij S, van den Brink EN, Kellner C, Riedl T, et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. MAbs in press [published online January 3, 2014; doi:104161/mabs27705].
23. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173:4699-707.
24. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8.
25. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998;12:3663-74.
26. Poncelet P, Carayon P. Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods 1985;85:65-74.
27. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad SciUS A 2013;110:5145-50.
28. Mandal SK, Pendurthi UR, Rao LV. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007;110:161-70.
29. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.
30. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996;12:575-625.
31. Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Vijaya Mohan Rao L. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999;274:36995-7003.
32. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66:7630-8.
33. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressingmelanotransferrin/p97. Mol Cancer Ther 2006;5:1474-82.
34. Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem 2005;280:32499-504.
35. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013;81:113-21.
36. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37.
37. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor bymelanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992;89:11832-6.
38. Hamik A, Setiadi H, Bu G, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factormediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999;274:4962-9.
39. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008;314:3093-106.
40. Rao LVM, Pendurthi UR. Regulation of tissue factor-factor VIIa expression on cell surfaces: A role for tissue factor-factor VIIa endocytosis. Mol Cell Biochem 2003;253:131-40.
41. Chang GT, Kisiel W. Internalization and degradation of recombinant human coagulation factor VIIa by the human hepatoma cell line HuH7. Thromb Haemost 1995;73:231-8.
42. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009;101:2023-9.
43. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011;187:3383-90.
44. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 2003;22:537-47.
45. Wei SH, Ming-Lum A, Liu Y, Wallach D, Ong CJ, Chung SW, et al. Proteasome-mediated proteolysis of the interleukin-10 receptor is important for signal downregulation. J Interferon Cytokine Res 2006;26:281-90.